Nature Biotechnology 24, 729 (2006)
Published online: 6 July 2006; | doi:10.1038/nbt0706-729
Pipeline cherrypicking deal yields lucrative returnJohn Ransom
Lone Tree, Colorado
Exelixis is reaping the benefits of a licensing and development deal with GlaxoSmithKline that gives the pharma partner an option on 3 of 12 specified products in development.
|
